Targeting RAS–ERK signalling in cancer: promises and challenges
The DOI matches its Crossref record; 139 of the 139 references it cites were found in a registry or an index.
Abstract
The RAS-RAF-MEK-ERK signalling pathway is hyperactivated in a high percentage of tumours, most frequently owing to activating mutations of the KRAS, NRAS and BRAF genes. Recently, the use of compounds targeting components of ERK signalling, such as RAF or MEK inhibitors, has led to substantial improvement in clinical outcome in metastatic melanoma and has shown promising clinical activity in additional tumour types. However, response rates are highly variable and the efficacy of these drugs is primarily limited by the development of resistance. Both intrinsic and acquired resistance to RAF and MEK inhibitors are frequently associated with the persistence of ERK signalling in the presence of the drug, implying the need for more innovative approaches to target the pathway.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The activity of single agent therapies targeting individual RAS effector pathways is limited”
From A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution (2017) · cites this paper as Samatar and Poulikakos, 2014
In the citing paper
“combinations of inhibitors targeting multiple effector and/or feedback pathways have shown impressive activity in KRAS mutant model systems”
From A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution (2017) · cites this paper as Samatar and Poulikakos, 2014
In the citing paper
“Determinants of primary resistance are not the same in different tumor types that up-regulate various RTKs or their ligands in response to pathway inhibition (111-113).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [113]
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
MAP kinase signalling pathways in cancer
Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995
Hauschild, A., Grob, J.-J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C. U., Miller, W. H., Kaempgen, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60868-x · Cited by 2,989
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M.-K., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,192
Cited by
Baracos, V. E., Martin, L., Korc, M., Guttridge, D. C., & Fearon, K. C. H. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.105 · Cited by 1,738
Comprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
RAS isoforms and mutations in cancer at a glance
Hobbs, G. A., Der, C. J., & Rossman, K. L. (2016) · Journal of Cell Science · doi:10.1242/jcs.182873 · Cited by 973
“…delta) (Zimmermann et al., 2013), (iii) inhibitors of downstream effector signaling (e.g. RAF or PI3K effectors) (Fruman and Rommel, 2014; Samatar and Poulikakos, 2014), (iv) inhibitors of processes that support the increased metabolic needs of cancer cells (e.g. macropinocytosis,…”
BackgroundTargeting CDK4 and CDK6: From Discovery to Therapy
Sherr, C. J., Beach, D., & Shapiro, G. I. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0894 · Cited by 936
KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer
Waters, A. M., & Der, C. J. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031435 · Cited by 875
5-methylcytosine promotes pathogenesis of bladder cancer through stabilizing mRNAs
Chen, X., Li, A., Sun, B.-F., Yang, Y., Han, Y.-N., Yuan, X., Chen, R.-X., Wei, W.-S., Liu, Y., Gao, C.-C., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0361-y · Cited by 801
PROTACs: great opportunities for academia and industry
Sun, X., Gao, H., Yang, Y., He, M., Wu, Y., Song, Y., Tong, Y., & Rao, Y. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0101-6 · Cited by 613
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
Caunt, C. J., Sale, M. J., Smith, P. D., & Cook, S. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4000 · Cited by 606
RAF-MEK-ERK pathway in cancer evolution and treatment
Ullah, R., Yin, Q., Snell, A. H., & Wan, L. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.05.010 · Cited by 553
Lampi, M. C., & Reinhart-King, C. A. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao0475 · Cited by 551
Targeting the MAPK pathway in KRAS-driven tumors
Drosten, M., & Barbacid, M. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.013 · Cited by 512
Banerjee, M., Cui, X., Li, Z., Yu, H., Cai, L., Jia, X., He, D., Wang, C., Gao, T., & Xie, Z. (2018) · Scientific Reports · doi:10.1038/s41598-018-29995-2 · Cited by 506
(2023) · doi:10.1038/s41392-022-01304-4 · Cited by 460
Zhong, Z., Huang, M., Lv, M., He, Y., Duan, C., Zhang, L., & Chen, J. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.06.027 · Cited by 449
Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy
Liu, F., Yang, X., Geng, M., & Huang, M. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.01.008 · Cited by 432
Opportunities for Tapping into Three-Dimensional Chemical Space through a Quaternary Carbon
Talele, T. T. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00829 · Cited by 424
NK cell–mediated cytotoxicity contributes to tumor control by a cytostatic drug combination
Ruscetti, M., Leibold, J., Bott, M. J., Fennell, M., Kulick, A., Salgado, N. R., Chen, C.-C., Ho, Y.-J., Sanchez-Rivera, F. J., Feucht, J., et al. (2018) · Science · doi:10.1126/science.aas9090 · Cited by 415
Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras
Lebraud, H., Wright, D. J., Johnson, C. N., & Heightman, T. D. (2016) · ACS Central Science · doi:10.1021/acscentsci.6b00280 · Cited by 413
“27,28 Although this signaling pathway is currently the subject of intense e ff orts in cancer research, exempli fi ed by the number of ERK1/2 inhibitors under development, 29 − 32 to the best of our knowledge ERK1/2 degradation has not been explored as a potential therapeutic strategy.”
Hu, K., Li, K., Lv, J., Feng, J., Chen, J., Wu, H., Cheng, F., Jiang, W., Wang, J., Pei, H., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci124049 · Cited by 404
New perspectives for targeting RAF kinase in human cancer
Karoulia, Z., Gavathiotis, E., & Poulikakos, P. I. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.79 · Cited by 404
Self-citationA combinatorial strategy for treating KRAS-mutant lung cancer
Manchado, E., Weissmueller, S., Morris, J. P., Chen, C.-C., Wullenkord, R., Lujambio, A., de Stanchina, E., Poirier, J. T., Gainor, J. F., Corcoran, R. B., et al. (2016) · Nature · doi:10.1038/nature18600 · Cited by 403
“Several RTKs have been implicated in adaptive resistance to RAS pathway antagonist 8,9,11,15–20 .”
Papke, B., & Der, C. J. (2017) · Science · doi:10.1126/science.aam7622 · Cited by 399
Molecular Mechanisms of Colon Cancer Progression and Metastasis: Recent Insights and Advancements
Malki, A., ElRuz, R. A., Gupta, I., Allouch, A., Vranic, S., & Al Moustafa, A.-E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010130 · Cited by 398
CCL5/CCR5 axis in human diseases and related treatments
Zeng, Z., Lan, T., Wei, Y., & Wei, X. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2021.08.004 · Cited by 378
Sugiura, R., Satoh, R., & Takasaki, T. (2021) · Cells · doi:10.3390/cells10102509 · Cited by 369
Proteolysis-targeting chimeras (PROTACs) in cancer therapy
Li, X., Pu, W., Zheng, Q., Ai, M., Chen, S., & Peng, Y. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01434-3 · Cited by 337
Jiang, G.-M., Tan, Y., Wang, H., Peng, L., Chen, H.-T., Meng, X.-J., Li, L.-L., Liu, Y., Li, W.-F., & Shan, H. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0944-z · Cited by 365
Ras Conformational Ensembles, Allostery, and Signaling
Lu, S., Jang, H., Muratcioglu, S., Gursoy, A., Keskin, O., Nussinov, R., & Zhang, J. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00542 · Cited by 355
Chen, H.-T., Liu, H., Mao, M.-J., Tan, Y., Mo, X.-Q., Meng, X.-J., Cao, M.-T., Zhong, C.-Y., Liu, Y., Shan, H., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1030-2 · Cited by 333
Drosophila melanogaster: A Model Organism to Study Cancer
Mirzoyan, Z., Sollazzo, M., Allocca, M., Valenza, A. M., Grifoni, D., & Bellosta, P. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00051 · Cited by 317
Targeting ERK1/2 protein-serine/threonine kinases in human cancers
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.01.039 · Cited by 308
Pietrobono, S., Gagliardi, S., & Stecca, B. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00556 · Cited by 303
KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target
Román, M., Baraibar, I., López, I., Nadal, E., Rolfo, C., Vicent, S., & Gil-Bazo, I. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0789-x · Cited by 301
ACE2 inhibits breast cancer angiogenesis via suppressing the VEGFa/VEGFR2/ERK pathway
Zhang, Q., Lu, S., Li, T., Yu, L., Zhang, Y., Zeng, H., Qian, X., Bi, J., & Lin, Y. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1156-5 · Cited by 297
Tan, G., Huang, C., Chen, J., & Zhi, F. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00985-0 · Cited by 290
Ganly, I., Makarov, V., Deraje, S., Dong, Y., Reznik, E., Seshan, V., Nanjangud, G., Eng, S., Bose, P., Kuo, F., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.07.002 · Cited by 283
Modulators of 14-3-3 Protein–Protein Interactions
Stevers, L. M., Sijbesma, E., Botta, M., MacKintosh, C., Obsil, T., Landrieu, I., Cau, Y., Wilson, A. J., Karawajczyk, A., Eickhoff, J., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00574 · Cited by 279
The Upstream Pathway of mTOR-Mediated Autophagy in Liver Diseases
Wang, H., Liu, Y., Wang, D., Xu, Y., Dong, R., Yang, Y., Lv, Q., Chen, X., & Zhang, Z. (2019) · Cells · doi:10.3390/cells8121597 · Cited by 279
KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS
Ambrogio, C., Köhler, J., Zhou, Z.-W., Wang, H., Paranal, R., Li, J., Capelletti, M., Caffarra, C., Li, S., Lv, Q., et al. (2018) · Cell · doi:10.1016/j.cell.2017.12.020 · Cited by 270
“…MEK and ERK inhibitors (Köhler et al., 2017), and in vitro evidence suggests that the lack of clinical efficacy is due to a combination of narrow therapeutic windows, the genetic context, relief of feedback inhibition on upstream kinases, and intrinsic resistance (Samatar and Poulikakos, 2014).”
BackgroundHayes, T. K., Neel, N. F., Hu, C., Gautam, P., Chenard, M., Long, B., Aziz, M., Kassner, M., Bryant, K. L., Pierobon, M., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2015.11.011 · Cited by 264
Self-citationTargeted therapy for head and neck cancer: signaling pathways and clinical studies
Li, Q., Tie, Y., Alu, A., Ma, X., & Shi, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01297-0 · Cited by 253
Cellular Senescence and the Senescence-Associated Secretory Phenotype as Drivers of Skin Photoaging
Fitsiou, E., Pulido, T., Campisi, J., Alimirah, F., & Demaria, M. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.09.031 · Cited by 227
Ahmed, T. A., Adamopoulos, C., Karoulia, Z., Wu, X., Sachidanandam, R., Aaronson, S. A., & Poulikakos, P. I. (2019) · Cell Reports · doi:10.1016/j.celrep.2018.12.013 · Cited by 214
“Activation of RTK signaling has been found to drive adaptive resistance in various ERK-dependent tumor contexts, including BRAF(V600E) melanoma, colorectal and thyroid cancers, and TNBC and RAS mutant tumors (Chandarlapaty, 2012; Corcoran et al., 2012; Duncan et al., 2012; Karoulia et al., 2016, 2017; Lito et al., 201…”
Self-citationTargeting RAS–RAF–MEK–ERK signaling pathway in human cancer: Current status in clinical trials
Song, Y., Bi, Z., Liu, Y., Qin, F., Wei, Y., & Wei, X. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.05.006 · Cited by 212
HSF1: Guardian of Proteostasis in Cancer
Dai, C., & Sampson, S. B. (2016) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.10.011 · Cited by 210
Huang, J.-L., Jiang, G., Song, Q.-X., Gu, X., Hu, M., Wang, X.-L., Song, H.-H., Chen, L.-P., Lin, Y.-Y., Jiang, D., et al. (2017) · Nature Communications · doi:10.1038/ncomms15144 · Cited by 209
Allosteric small-molecule kinase inhibitors
Wu, P., Clausen, M. H., & Nielsen, T. E. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.10.002 · Cited by 204
Karoulia, Z., Wu, Y., Ahmed, T. A., Xin, Q., Bollard, J., Krepler, C., Wu, X., Zhang, C., Bollag, G., Herlyn, M., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.06.024 · Cited by 205
“This is the basis of the high therapeutic index of these drugs, but RAF dimerization is also predicted to result in drug resistance (Poulikakos et al., 2010; Samatar and Poulikakos, 2014).”
Self-citationSu, J., Wu, G., Ye, Y., Zhang, J., Zeng, L., Huang, X., Zheng, Y., Bai, R., Zhuang, L., Li, M., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01978-0 · Cited by 196
Targeting oncogenic Raf protein-serine/threonine kinases in human cancers
Roskoski, R. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.08.013 · Cited by 194
Optical control of cell signaling by single-chain photoswitchable kinases
Zhou, X. X., Fan, L. Z., Li, P., Shen, K., & Lin, M. Z. (2017) · Science · doi:10.1126/science.aah3605 · Cited by 196
Wang, Q.-M., Lian, G.-Y., Song, Y., Huang, Y.-F., & Gong, Y. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.03.040 · Cited by 194
MEK inhibitors activate Wnt signalling and induce stem cell plasticity in colorectal cancer
Zhan, T., Ambrosi, G., Wandmacher, A. M., Rauscher, B., Betge, J., Rindtorff, N., Häussler, R. S., Hinsenkamp, I., Bamberg, L., Hessling, B., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09898-0 · Cited by 189
Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view
Lu, S., Jang, H., Gu, S., Zhang, J., & Nussinov, R. (2016) · Chemical Society Reviews · doi:10.1039/c5cs00911a · Cited by 188
Shen, F., Song, Z., Xie, P., Li, L., Wang, B., Peng, D., & Zhu, G. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114164 · Cited by 186
RAS-mediated oncogenic signaling pathways in human malignancies
Khan, A. Q., Kuttikrishnan, S., Siveen, K. S., Prabhu, K. S., Shanmugakonar, M., Al- Naemi, H. A., Haris, M., Dermime, S., & Uddin, S. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.03.001 · Cited by 179
Zhang, J., Chen, B., Gan, C., Sun, H., Zhang, J., & Feng, L. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s436038 · Cited by 174
KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment
Zeitouni, D., Pylayeva-Gupta, Y., Der, C., & Bryant, K. (2016) · Cancers · doi:10.3390/cancers8040045 · Cited by 179
Telonis, A. G., Loher, P., Jing, Y., Londin, E., & Rigoutsos, I. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv922 · Cited by 178
Lu, N., & Malemud, C. J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153792 · Cited by 175
Park, J., Yang, J., Wenzel, A. T., Ramachandran, A., Lee, W. J., Daniels, J. C., Kim, J., Martinez-Escala, E., Amankulor, N., Pro, B., et al. (2017) · Blood · doi:10.1182/blood-2017-02-768234 · Cited by 172
Trametinib: a MEK inhibitor for management of metastatic melanoma
Rutkowski, P., Lugowska, I., Kosela-Paterczyk, H., & Kozak, K. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s72951 · Cited by 171
BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall
Leonetti, A., Facchinetti, F., Rossi, G., Minari, R., Conti, A., Friboulet, L., Tiseo, M., & Planchard, D. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.04.006 · Cited by 168
Zhang, X., Chen, L., Dang, W.-Q., Cao, M.-F., Xiao, J.-F., Lv, S.-Q., Jiang, W.-J., Yao, X.-H., Lu, H.-M., Miao, J.-Y., et al. (2020) · Laboratory Investigation · doi:10.1038/s41374-019-0345-3 · Cited by 163
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment
Petroni, G., Buqué, A., Coussens, L. M., & Galluzzi, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00415-5 · Cited by 160
McClain, K. L., Bigenwald, C., Collin, M., Haroche, J., Marsh, R. A., Merad, M., Picarsic, J., Ribeiro, K. B., & Allen, C. E. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00307-9 · Cited by 159
The role of autophagy in hepatocellular carcinoma: friend or foe
Liu, L., Liao, J., He, X., & Li, P. (2017) · Oncotarget · doi:10.18632/oncotarget.17202 · Cited by 166
Rather, R. A., & Bhagat, M. (2019) · Cancer Medicine · doi:10.1002/cam4.1411 · Cited by 168
Moschos, S. J., Sullivan, R. J., Hwu, W.-J., Ramanathan, R. K., Adjei, A. A., Fong, P. C., Shapira-Frommer, R., Tawbi, H. A., Rubino, J., Rush, T. S., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.92352 · Cited by 147
Self-citationTargeting Apoptosis and Multiple Signaling Pathways with Icariside II in Cancer Cells
Khan, M. N., Maryam, A., Qazi, J. I., & Ma, T. (2015) · International Journal of Biological Sciences · doi:10.7150/ijbs.11595 · Cited by 155
BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors
Schreck, K. C., Grossman, S. A., & Pratilas, C. A. (2019) · Cancers · doi:10.3390/cancers11091262 · Cited by 147
Molecular Pathways and Mechanisms of BRAF in Cancer Therapy
Poulikakos, P. I., Sullivan, R. J., & Yaeger, R. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2138 · Cited by 145
Self-citationDerepression of hTERT gene expression promotes escape from oncogene-induced cellular senescence
Patel, P. L., Suram, A., Mirani, N., Bischof, O., & Herbig, U. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1602379113 · Cited by 142
“In addition, because Ras–MAP kinase signaling is essential for hTERT expression in cells that had escaped OIS, conventional inhibitors of this signaling pathway may even be effective in inhibiting telomerase activity in early transformed human cancer cells, as our data would suggest (51).”
ResultCompetition for Space Induces Cell Elimination through Compaction-Driven ERK Downregulation
Moreno, E., Valon, L., Levillayer, F., & Levayer, R. (2018) · Current Biology · doi:10.1016/j.cub.2018.11.007 · Cited by 158
The Role of ERK1/2 in the Development of Diabetic Cardiomyopathy
Xu, Z., Sun, J., Tong, Q., Lin, Q., Qian, L.-B., Park, Y., & Zheng, Y. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122001 · Cited by 137
Metastatic Melanoma: Insights Into the Evolution of the Treatments and Future Challenges
Millet, A., Martin, A. R., Ronco, C., Rocchi, S., & Benhida, R. (2016) · Medicinal Research Reviews · doi:10.1002/med.21404 · Cited by 142
Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma
Yu, C., Liu, X., Yang, J., Zhang, M., Jin, H., Ma, X., & Shi, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00990 · Cited by 126
Oddo, D., Sennott, E. M., Barault, L., Valtorta, E., Arena, S., Cassingena, A., Filiciotto, G., Marzolla, G., Elez, E., van Geel, R. M. J. M., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0396 · Cited by 121
Roskoski, R. J. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.12.009 · Cited by 125
Sanclemente, M., Francoz, S., Esteban-Burgos, L., Bousquet-Mur, E., Djurec, M., Lopez-Casas, P. P., Hidalgo, M., Guerra, C., Drosten, M., Musteanu, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2017.12.014 · Cited by 119
Signaling, metabolism, and cancer: An important relationship for therapeutic intervention
Vaghari‐Tabari, M., Ferns, G. A., Qujeq, D., Andevari, A. N., Sabahi, Z., & Moein, S. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30276 · Cited by 143
Tetrandrine and cancer – An overview on the molecular approach
Bhagya, N., & Chandrashekar, K. R. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.10.116 · Cited by 114
Huang, Z., Pan, J., Wang, H., Du, X., Xu, Y., Wang, Z., & Chen, D. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.657547 · Cited by 135
MicroRNA-31 initiates lung tumorigenesis and promotes mutant KRAS-driven lung cancer
Edmonds, M. D., Boyd, K. L., Moyo, T. K., Mitra, R., Duszynski, R. J., Arrate, M. P., Chen, X., Zhao, Z., Blackwell, T. S., Andl, T., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci82720 · Cited by 109
Allen, C. E., Laetsch, T. W., Mody, R. J., Irwin, M. S., Lim, M. S., Adamson, P. C., Seibel, N. L., Parsons, D. W., Cho, Y., & Janeway, K. A. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw274 · Cited by 118
Chen, Z., Zuo, X., Zhang, Y., Han, G., Zhang, L., Wu, J., & Wang, X. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0616-8 · Cited by 110
Gomes, A. P., Ilter, D., Low, V., Rosenzweig, A., Shen, Z.-J., Schild, T., Rivas, M. A., Er, E. E., McNally, D. R., Mutvei, A. P., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.08.006 · Cited by 106
Sun, Y., Alberta, J. A., Pilarz, C., Calligaris, D., Chadwick, E. J., Ramkissoon, S. H., Ramkissoon, L. A., Garcia, V. M., Mazzola, E., Goumnerova, L., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/now261 · Cited by 105
Miyamoto, Y., Suyama, K., & Baba, H. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040752 · Cited by 106
Ozkan-Dagliyan, I., Diehl, J. N., George, S. D., Schaefer, A., Papke, B., Klotz-Noack, K., Waters, A. M., Goodwin, C. M., Gautam, P., Pierobon, M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107764 · Cited by 106
GLI1: A Therapeutic Target for Cancer
Avery, J. T., Zhang, R., & Boohaker, R. J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.673154 · Cited by 115
Choi, H. Y., Yang, G., Dayem, A. A., Saha, S. K., Kim, K., Yoo, Y.-B., Hong, K., Kim, J., Yee, C., Lee, K., et al. (2019) · Breast Cancer Research · doi:10.1186/s13058-018-1071-2 · Cited by 113
Inhibition of ERK1/2 down-regulates the Hippo/YAP signaling pathway in human NSCLC cells
You, B., Yang, Y., Xu, Z., Dai, Y., Liu, S., Mao, J., Tetsu, O., Li, H., Jablons, D. M., & You, L. (2015) · Oncotarget · doi:10.18632/oncotarget.2974 · Cited by 112
Dong, Q., Yang, B., Han, J.-G., Zhang, M., Liu, W., Zhang, X., Yu, H., Liu, Z., Zhang, S., Li, T., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.04.031 · Cited by 106
Li, Y., Cheng, H. S., Chng, W. J., & Tergaonkar, V. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1611106113 · Cited by 104
Tight Junction Proteins Claudin-1 and Occludin Are Important for Cutaneous Wound Healing
Volksdorf, T., Heilmann, J., Eming, S. A., Schawjinski, K., Zorn‐Kruppa, M., Ueck, C., Vidal‐y‐Sy, S., Windhorst, S., Jücker, M., Moll, I., et al. (2017) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.02.006 · Cited by 109
Mitogen-activated protein kinase signaling pathway in oral cancer (Review)
Peng, Q., Deng, Z., Pan, H., Gu, L., Liu, O., & Tang, Z. (2017) · Oncology Letters · doi:10.3892/ol.2017.7491 · Cited by 141
Current Insights of BRAF Inhibitors in Cancer
Agianian, B., & Gavathiotis, E. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01306 · Cited by 112
Zhang, X., Cai, D., Zhou, F., Yu, J., Wu, X., Yu, D., Zou, Y., Hong, Y., Yuan, C., Chen, Y., et al. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119724 · Cited by 107
Iatrogenic endometriosis harbors somatic cancer-driver mutations
Lac, V, Verhoef, L., Aguirre-Hernandez, R., Nazeran, T. M., Tessier-Cloutier, B., Praetorius, T., Orr, N. L., Noga, H., Lum, A., Khattra, J., et al. (2019) · Human Reproduction · doi:10.1093/humrep/dey332 · Cited by 99
Metadata
- Authors
- Samatar, A. A., & Poulikakos, P. I.
- Affiliations
- Tisch Cancer Institute (US)
- Corresponding author
- Poulikakos, Poulikos I.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-12
- Volume
- 13
- Issue
- 12
- Pages
- 928-942
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2050573392
- Cited by
- 1,163
- References
- 139
- Citations by year
- 2026: 47 · 2025: 77 · 2024: 106 · 2023: 100 · 2022: 102 · 2021: 134 · 2020: 119 · 2019: 105 · 2018: 117 · 2017: 101 · 2016: 108 · 2015: 45 · 2014: 2
- FWCI
- 8.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- RAF inhibitors, MEK inhibitors, ERK inhibitor, KRAS mutation, NRAS mutation, BRAF mutation, acquired drug resistance, intrinsic drug resistance, metastatic melanoma, targeted cancer therapy, drug development
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Neoplasms, Drug Delivery Systems, ras Proteins, MAP Kinase Signaling System, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.